H. R. 1706

To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MARCH 25, 2009

Mr. Rush (for himself, Mr. Waxman, Mr. Dingell, Mr. Doyle, Mr. Markey of Massachusetts, Mr. Stupak, Ms. Schakowsky, and Ms. DeGette) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

A BILL

To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes.

1 Be it enacted by the Senate and House of Representa-
2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the “Protecting Consumer
5 Access to Generic Drugs Act of 2009”.

SEC. 2. UNFAIR AND DECEPTIVE ACTS AND PRACTICES RELATED TO NEW DRUG APPLICATIONS.

(a) Conduct Prohibited.—It shall be unlawful for any person to directly or indirectly be a party to any agreement resolving or settling a patent infringement claim in which—

(1) an ANDA filer receives anything of value; and

(2) the ANDA filer agrees not to research, develop, manufacture, market, or sell, for any period of time, the drug that is to be manufactured under the ANDA involved and is the subject of the patent infringement claim.

(b) Exceptions.—Notwithstanding subsection (a)(1), subsection (a) does not prohibit a resolution or settlement of a patent infringement claim in which the value received by the ANDA filer includes no more than—

(1) the right to market the drug that is to be manufactured under the ANDA involved and is the subject of the patent infringement claim, before the expiration of—

(A) the patent that is the basis for the patent infringement claim; or

(B) any other statutory exclusivity that would prevent the marketing of such drug; and
(2) the waiver of a patent infringement claim
for damages based on prior marketing of such drug.

(c) ENFORCEMENT.—A violation of subsection (a)
shall be treated as an unfair and deceptive act or practice
and an unfair method of competition in or affecting inter-
state commerce prohibited under section 5 of the Federal
Commission shall enforce this Act in the same manner,
by the same means, and with the same jurisdiction as
though all applicable terms and provisions of the Federal
Trade Commission Act were incorporated into and made
a part of this Act.

(d) DEFINITIONS.—In this section:

(1) AGREEMENT.—The term “agreement”
means anything that would constitute an agreement
for purposes of section 5 of the Federal Trade Com-

(2) AGREEMENT RESOLVING OR SETTLING.—
The term “agreement resolving or settling”, in ref-
ference to a patent infringement claim, includes any
agreement that is contingent upon, provides a con-
tingent condition for, or is otherwise related to the
resolution or settlement of the claim.

(3) ANDA.—The term “ANDA” means an ab-
abbreviated new drug application for the approval of a
new drug under section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)).

(4) ANDA FILER.—The term “ANDA filer” means a party that has filed an ANDA with the Food and Drug Administration.

(5) PATENT INFRINGEMENT.—The term “patent infringement” means infringement of any patent or of any filed patent application, extension, reissuance, renewal, division, continuation, continuation in part, reexamination, patent term restoration, patent of addition, or extension thereof.

(6) PATENT INFRINGEMENT CLAIM.—The term “patent infringement claim” means any allegation made to an ANDA filer, whether or not included in a complaint filed with a court of law, that its ANDA or drug to be manufactured under such ANDA may infringe any patent.

SEC. 3. FTC RULEMAKING.

The Federal Trade Commission may, by rule promulgated under section 553 of title 5, United States Code, exempt certain agreements described in section 2 if the Commission finds such agreements to be in furtherance of market competition and for the benefit of consumers. Consistent with the authority of the Commission, such rules may include interpretive rules and general state-
ments of policy with respect to the practices prohibited under section 2.

SEC. 4. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD UNDER THE FFDCA.


(1) in subclause (I)(bb)—

(A) by redesignating subitem (CC) as subitem (EE); and

(B) by inserting after subitem (BB) the following:

“(CC) In a declaratory judgment action described in subitem (AA), a court dismisses the action for lack of subject matter jurisdiction, either with or without prejudice.

“(DD) The applicant files with the Secretary a covenant by the patent owner that the patent owner will not sue the applicant for
infringement with respect to
the patent.”; and
(2) in subclause (V), by inserting “section 2 of
the Protecting Consumer Access to Generic Drugs
Act of 2009 or” after “that the agreement has vio-
lated”.

SEC. 5. NOTICE AND CERTIFICATION OF AGREEMENTS.
(a) Notice of all agreements.—Section
1112(c)(2) of the Medicare Prescription Drug, Improve-
ment, and Modernization Act of 2003 (21 U.S.C. 3155
note) is amended by—
(1) striking “the Commission the” and insert-
ing “the Commission (1) the”; and
(2) inserting before the period at the end the
following: “; and (2) a description of the subject
matter of any other agreement the parties enter into
within 30 days of an entering into an agreement
covered by subsection (a) or (b)”.
(b) Certification of agreements.—Section 1112
of such Act is amended by adding at the end the following:
“(d) Certification.—The Chief Executive Officer
or the company official responsible for negotiating any
agreement required to be filed under subsection (a), (b),
or (c) shall execute and file with the Assistant Attorney
General and the Commission a certification as follows: ‘I
declare under penalty of perjury that the following is true
and correct: The materials filed with the Federal Trade
Commission and the Department of Justice under section
1112 of subtitle B of title XI of the Medicare Prescription
Drug, Improvement, and Modernization Act of 2003, with
respect to the agreement referenced in this certification:
(1) represent the complete, final, and exclusive agreement
between the parties; (2) include any ancillary agreements
that are contingent upon, provide a contingent condition
for, or are otherwise related to, the referenced agreement;
and (3) include written descriptions of any oral agree-
ments, representations, commitments, or promises be-
tween the parties that are responsive to subsection (a) or
(b) of such section 1112 and have not been reduced to
writing.".".

○